← All trials
NCT05358509
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2021
- Primary completion
- Jan 31, 2024
- Completion date
- Jun 30, 2024
- First posted
- May 3, 2022
- Last posted
- May 3, 2022
- Enrollment
- 4320
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Thomas Jefferson UniversityLead sponsor
- The Children's Investment Fund FoundationCollaborator
- Jawaharlal Nehru Medical CollegeCollaborator
- Rajasthan University of Health SciencesCollaborator
- S. Nijalingappa Medical CollegeCollaborator
- Thomas Jefferson UniversityOverall official - principal investigator
- Thomas Jefferson UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.